CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.

Stefanie SeitzTobias F DreyerChristoph StangeKatja SteigerRosalinde BräuerLeandra ScheutzGabriele MulthoffWilko WeichertMarion KiechleViktor MagdolenHolger Bronger

Published in: British journal of cancer (2022)

CXCL9 is a driver of successful ICB in preclinical ovarian cancer. Besides being a feasible predictive biomarker, CXCL9-inducing agents thus represent attractive combination partners to improve ICB in this cancer entity.

Keyphrases

papillary thyroid
squamous cell
cell therapy
stem cells
mesenchymal stem cells
hiv testing
hepatitis c virus
human immunodeficiency virus
childhood cancer